IMAB

$0.00

(

0.00%

)
Quote details

stock

I-Mab

NASDAQ | IMAB

4.63

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$533.68M

Market Cap

-

P/E Ratio

-0.51

EPS

$6.79

52 Week High

$0.59

52 Week Low

HEALTHCARE

Sector

IMAB Chart

Recent Chart
Price Action

IMAB Technicals

Tags:

IMAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

Revenue & Profitability

Earnings Performance

IMAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $177M
Cash And Cash Equivalents At Carrying Value $68M
Cash And Short Term Investments $68M
Inventory -
Current Net Receivables $1.2M
Total Non Current Assets $36M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $31M
Short Term Investments $105M
Other Current Assets $2.1M
Other Non Current Assets -
Total Liabilities $12M
Total Current Liabilities $8.5M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $816K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $3.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.9M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $201M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $19K
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$53M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $978K
Capital Expenditures $48K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$136M
Cashflow From Financing -$335K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$335K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$50M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

IMAB Profile

I-Mab Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the potential to drive meaningful advancements in healthcare and improve patient outcomes.

VHAI
+100.00%
$0.00
LPTX
+368.57%
$2.05
NVDA
-0.97%
$178.88
IVP
-2.25%
$0.12
NVVE
+55.88%
$0.25
IVDA
+34.66%
$0.87
TWOH
-34.78%
$0.00
DVLT
+46.55%
$2.55
ONDS
+7.41%
$6.73
OSRH
+23.37%
$0.56
PLUG
+4.76%
$1.98
INTC
+2.61%
$34.50
TSLA
-1.04%
$391.09
SOFI
+1.12%
$25.19
ASST
+3.78%
$1.02
BITF
-6.53%
$2.43
BYND
-2.00%
$0.86
F
+3.38%
$12.83
GOOGL
+3.52%
$299.66
PFE
+2.62%
$25.04
GRAB
-1.60%
$4.90
CCTG
+43.01%
$0.23
PLTR
-0.57%
$154.85
AMZN
+1.63%
$220.69
MNDR
+56.25%
$4.75
AXDX
-61.36%
$0.03
AMD
-1.08%
$203.78
DNN
-2.15%
$2.27
AAL
+5.14%
$12.87
SGMO
+9.97%
$0.42
ACHR
+4.51%
$7.18
AAPL
+1.96%
$271.49
T
+1.60%
$25.93
MARA
-1.66%
$10.07
CIFR
-2.81%
$14.15
NIO
+3.33%
$5.58
BMNR
-0.07%
$26.00
BBD
0.00%
$3.48
NWTN
-5.10%
$0.74
AIIO
-5.10%
$0.74
RGTI
+3.46%
$23.59
SOUN
-0.62%
$11.22
ADAP
-15.14%
$0.05
WULF
-2.33%
$11.29
IREN
-2.78%
$42.26
KVUE
+3.03%
$16.64
NOK
+1.19%
$5.94
ORCL
-5.66%
$198.76
PCG
-1.07%
$15.67
BAC
+1.09%
$51.56
GOOG
+3.33%
$299.65
VALE
+1.42%
$12.09
WMT
-1.67%
$105.32
SNAP
-1.15%
$7.69
NFLX
-1.28%
$104.31
BTBT
+1.95%
$2.09
QBTS
-0.48%
$20.41
RIVN
+1.36%
$14.86
HOOD
+1.02%
$107.30
RMBL
+60.50%
$3.21
SOND
-23.45%
$0.12
RIG
+1.30%
$3.89
GPUS
+21.57%
$0.25
LNW
-3.71%
$86.22
CRWV
+3.52%
$71.65
ABEV
+2.05%
$2.48
ADD
-25.47%
$0.05
WBD
+1.26%
$23.17
APLD
-1.31%
$21.09
NFE
-17.12%
$1.21
IONZ
-4.67%
$6.12
MU
+2.97%
$207.37
BULL
+0.48%
$8.29
SRM
+53.27%
$10.30
NBIS
-1.63%
$83.26
PLTD
+0.52%
$7.67
UBER
+0.61%
$83.87
RXRX
+8.31%
$4.17
CGC
+9.90%
$1.11
HBAN
+3.65%
$15.88
BMNU
-2.04%
$5.26
VZ
+1.15%
$41.23
QS
-2.13%
$11.47
MSFT
-1.31%
$472.12
BTE
+0.63%
$3.18
EOSE
-4.03%
$12.36
AVGO
-1.90%
$340.20
PLTZ
+1.06%
$8.57
BURU
+8.33%
$0.20
MSTR
-3.74%
$170.50
IONQ
+1.73%
$41.71
TLRY
+0.75%
$0.90
JOBY
+0.23%
$13.07
WLGS
-5.57%
$0.04
CLSK
-0.51%
$9.73
SMCI
+1.99%
$32.19
MTSR
-0.35%
$70.50
CAN
-1.49%
$0.90
BTG
+0.52%
$3.81
VIVK
+12.24%
$0.13
VHAI
+100.00%
$0.00
LPTX
+368.57%
$2.05
NVDA
-0.97%
$178.88
IVP
-2.25%
$0.12
NVVE
+55.88%
$0.25
IVDA
+34.66%
$0.87
TWOH
-34.78%
$0.00
DVLT
+46.55%
$2.55
ONDS
+7.41%
$6.73
OSRH
+23.37%
$0.56
PLUG
+4.76%
$1.98
INTC
+2.61%
$34.50
TSLA
-1.04%
$391.09
SOFI
+1.12%
$25.19
ASST
+3.78%
$1.02
BITF
-6.53%
$2.43
BYND
-2.00%
$0.86
F
+3.38%
$12.83
GOOGL
+3.52%
$299.66
PFE
+2.62%
$25.04
GRAB
-1.60%
$4.90
CCTG
+43.01%
$0.23
PLTR
-0.57%
$154.85
AMZN
+1.63%
$220.69
MNDR
+56.25%
$4.75
AXDX
-61.36%
$0.03
AMD
-1.08%
$203.78
DNN
-2.15%
$2.27
AAL
+5.14%
$12.87
SGMO
+9.97%
$0.42
ACHR
+4.51%
$7.18
AAPL
+1.96%
$271.49
T
+1.60%
$25.93
MARA
-1.66%
$10.07
CIFR
-2.81%
$14.15
NIO
+3.33%
$5.58
BMNR
-0.07%
$26.00
BBD
0.00%
$3.48
NWTN
-5.10%
$0.74
AIIO
-5.10%
$0.74
RGTI
+3.46%
$23.59
SOUN
-0.62%
$11.22
ADAP
-15.14%
$0.05
WULF
-2.33%
$11.29
IREN
-2.78%
$42.26
KVUE
+3.03%
$16.64
NOK
+1.19%
$5.94
ORCL
-5.66%
$198.76
PCG
-1.07%
$15.67
BAC
+1.09%
$51.56
GOOG
+3.33%
$299.65
VALE
+1.42%
$12.09
WMT
-1.67%
$105.32
SNAP
-1.15%
$7.69
NFLX
-1.28%
$104.31
BTBT
+1.95%
$2.09
QBTS
-0.48%
$20.41
RIVN
+1.36%
$14.86
HOOD
+1.02%
$107.30
RMBL
+60.50%
$3.21
SOND
-23.45%
$0.12
RIG
+1.30%
$3.89
GPUS
+21.57%
$0.25
LNW
-3.71%
$86.22
CRWV
+3.52%
$71.65
ABEV
+2.05%
$2.48
ADD
-25.47%
$0.05
WBD
+1.26%
$23.17
APLD
-1.31%
$21.09
NFE
-17.12%
$1.21
IONZ
-4.67%
$6.12
MU
+2.97%
$207.37
BULL
+0.48%
$8.29
SRM
+53.27%
$10.30
NBIS
-1.63%
$83.26
PLTD
+0.52%
$7.67
UBER
+0.61%
$83.87
RXRX
+8.31%
$4.17
CGC
+9.90%
$1.11
HBAN
+3.65%
$15.88
BMNU
-2.04%
$5.26
VZ
+1.15%
$41.23
QS
-2.13%
$11.47
MSFT
-1.31%
$472.12
BTE
+0.63%
$3.18
EOSE
-4.03%
$12.36
AVGO
-1.90%
$340.20
PLTZ
+1.06%
$8.57
BURU
+8.33%
$0.20
MSTR
-3.74%
$170.50
IONQ
+1.73%
$41.71
TLRY
+0.75%
$0.90
JOBY
+0.23%
$13.07
WLGS
-5.57%
$0.04
CLSK
-0.51%
$9.73
SMCI
+1.99%
$32.19
MTSR
-0.35%
$70.50
CAN
-1.49%
$0.90
BTG
+0.52%
$3.81
VIVK
+12.24%
$0.13

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.